((自动化翻译由路透提供，请见免责声明 ))
12月19日 - ** 药物开发商 Marker Therapeutics 股价盘前下跌 25.5% 至 3 美元
** MRKR宣布 (link) 1610万美元私募融资
** 此次融资所得款项将用于支持 MT-601 的临床开发，MT-601 是一种基于下一代 T 细胞的疗法，用于治疗复发淋巴瘤患者 - MRKR
** 投资者支付的购买价为 3.20 美元/每股，认股权证的行权价为 4.03 美元/每股
** 截至上次收盘，该公司股价已累计下跌 26.7
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.